|
|
|
Volumn 2, Issue 4, 1995, Pages 211-225
|
|
Rational development of turnout antigen-specific immunization in melanoma
|
|
Author keywords
Cancer; CTL; Immunotherapy; Melanoma; Vaccine
|
|
Indexed keywords
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;
TUMOR ANTIGEN;
TUMOR VACCINE;
CANCER VACCINE;
HLA ANTIGEN CLASS 1;
MAGEA3 PROTEIN, HUMAN;
TUMOR PROTEIN;
ACTIVE IMMUNIZATION;
ANTIGEN SPECIFICITY;
CANCER IMMUNIZATION;
CLINICAL TRIAL;
CYTOTOXIC T LYMPHOCYTE;
HELPER CELL;
HUMAN;
LYMPHOCYTE DIFFERENTIATION;
MELANOMA;
NONHUMAN;
PRIORITY JOURNAL;
REVIEW;
T LYMPHOCYTE ACTIVATION;
ANIMAL;
CELL DIFFERENTIATION;
CELL TRANSPLANTATION;
GENETIC TRANSFECTION;
IMMUNIZATION;
IMMUNOLOGY;
ANIMALS;
ANTIGENS, NEOPLASM;
CANCER VACCINES;
CELL DIFFERENTIATION;
CELL TRANSPLANTATION;
CLINICAL TRIALS;
HISTOCOMPATIBILITY ANTIGENS CLASS I;
HUMANS;
IMMUNIZATION;
IMMUNOTHERAPY, ACTIVE;
MELANOMA;
NEOPLASM PROTEINS;
T-LYMPHOCYTES, CYTOTOXIC;
TRANSFECTION;
|
|
EID: 0029414399
PISSN: 09670149
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (8)
|
|
References (121)
|
